Friedreich Ataxia Clinical Trial
Official title:
Characterization of the Interruptions of the GAA Expansion and Study of Their Influence on the Severity of Friedreich's Ataxia : INTREP-AF
Friedreich's ataxia (FA) is the most frequent recessive genetic ataxia with an estimated
prevalence of 1/50 000. The first symptoms appear around the age of 10 years with a
progressive course and the need for an armchair 10- 15 years after the first symptoms. More
rarely the disease can present with a late onset (after the age of 25) with a picture
characterized by spastic paraparesis and slower progression ("LOFA" for "Late Onset
Friedreich Ataxia" or VLOFA for "Very Late Appearance of Friedreich's ataxia ").
AF is caused in 96% of cases by an expansion of GAAN triplets (N> 100 repeats) located in
intron 1 of the FXN gene, present on the two alleles, and, in the rest of the cases, by an
associated expansion a point mutation or a deletion in trans. During molecular diagnostics,
it is not uncommon to find the presence of interruptions within the GAA expansion. This
results in the absence and / or the shift of peak (s) within the chromatogram.
To date, only the partial correlation between the size of the expansion and the age of onset
of Friedreich's ataxia has been established. In particular, very atypical forms of AF with a
late onset (after the age of 25) are in particular explained by the low number of repetitions
in the expansion, typically between 100 and 500 repetitions. However, the presence of an
interruption could stabilize the size of the expansion and, therefore, be mainly associated
with expansions of small sizes and therefore with a late onset of the disease.
The objective of this study is therefore to analyse and caracterize the presence and the type
of interruptions of the GAA expansions in a group of patients with FA ; this data will be
correlated with the age at onset of FA.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05573698 -
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
|
Phase 1 | |
| Completed |
NCT00229632 -
Idebenone to Treat Friedreich's Ataxia
|
Phase 2 | |
| Completed |
NCT05579691 -
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
|
Phase 2 | |
| Completed |
NCT04273165 -
Safety and Efficacy of Etravirine in Friedreich Ataxia Patients
|
Phase 2 | |
| Not yet recruiting |
NCT05874388 -
Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia
|
N/A | |
| Completed |
NCT02594917 -
Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension
|
||
| Completed |
NCT01716221 -
An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia
|
Phase 4 | |
| Active, not recruiting |
NCT05485987 -
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
|
Phase 2 | |
| Completed |
NCT03214588 -
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
|
Phase 2 | |
| Completed |
NCT03418740 -
Neurology Measures in FA Children
|
||
| Not yet recruiting |
NCT06054893 -
A Study of Omaveloxolone in Children With Friedreich's Ataxia
|
Phase 1 | |
| Recruiting |
NCT04921930 -
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03933163 -
Micronised Resveratrol as a Treatment for Friedreich Ataxia
|
Phase 2 | |
| Completed |
NCT02705547 -
Rosuvastatin (Crestor) in Friedreich Ataxia
|
Early Phase 1 | |
| Completed |
NCT02035020 -
A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients
|
Phase 2 | |
| Completed |
NCT00015808 -
Safety Study of Idebenone to Treat Friedreich's Ataxia
|
Phase 1 | |
| Completed |
NCT04817111 -
NAD+ Precursor Supplementation in Friedreich's Ataxia
|
Phase 2 | |
| Active, not recruiting |
NCT05168774 -
FRDA Investigator Initiated Study (IIS) With Elamipretide
|
Phase 1/Phase 2 | |
| Completed |
NCT03917225 -
A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
|
Phase 2 | |
| Completed |
NCT00224640 -
Iron-Chelating Therapy and Friedreich Ataxia
|
Phase 1/Phase 2 |